RxDoctor Payments Data

Kara Pate

Family · Albuquerque, NMNPI 1033609748

Payments from drug & device makers

$2,253in general payments, 2019–2025

Across 137 payments — averaging $16.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$424
  • Novo Nordisk$234
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$209
  • Avanir Pharmaceuticals, Inc.$191
  • Takeda Pharmaceuticals U.S.A., Inc.$174
  • Alpha Cognition USA, Inc.$153
  • plus $868 from 13 others

What the payments were for

  • Food & beverage$2,253100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,253 in reported general payments places this provider in the 90th percentile of 1,080 family providers in New Mexico.

See all family providers in New Mexico

Medicare billing

Part B allowed, 2024
$164,369
Medicare patients
224
Services billed
1,464

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban57$18,200
Spiriva RespimatTiotropium Bromide30$15,432
XareltoRivaroxaban41$11,377
JardianceEmpagliflozin25$7,670
JanuviaSitagliptin Phosphate23$6,692
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$4,731
Fluticasone-SalmeterolFluticasone Propion/Salmeterol26$3,569
Gabapentin81$2,978
Levetiracetam61$2,555
Aripiprazole14$2,514
Lactulose63$1,742
Memantine Hcl42$1,739
Levothyroxine Sodium145$1,666
Tamsulosin Hcl73$1,626
Albuterol Sulfate HfaAlbuterol Sulfate33$1,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
MerckJanuvia$61$6,69223 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,080 family providers in New Mexico.

Other family in Albuquerque

See the full list for New Mexico

Where these figures come from

Is this you, or does something look wrong? →